Applied Therapeutics Extends Tender Offer for Third Time, Nearing Majority Shareholder Acceptance

summarizeSummary

Applied Therapeutics has extended its tender offer by Cycle Group Holdings for a third time to February 2, 2026, with 49.21% of outstanding shares now tendered, moving closer to the majority condition for acquisition.

check_boxKey Events

• Tender Offer Extended

  The tender offer by AT2B, Inc. (a subsidiary of Cycle Group Holdings) has been extended for a third time, now set to expire on February 2, 2026.

• Nearing Majority Acceptance

  As of January 29, 2026, approximately 49.21% of Applied Therapeutics' outstanding shares have been validly tendered, up from 44.32% reported on January 29, 2026.

• Acquisition Terms Unchanged

  The offer price remains $0.088 per share in cash plus one non-tradeable contingent value right (CVR) with potential payments up to $0.40 per CVR.

auto_awesomeAnalysis

This SC TO-T/A filing provides a critical update on the ongoing tender offer by Cycle Group Holdings to acquire Applied Therapeutics. The extension marks the third time the offer deadline has been pushed, indicating challenges in securing the required majority of shares. However, the increase in tendered shares from 44.32% (reported on January 29) to 49.21% demonstrates significant progress towards the acquisition's completion. The offer, priced at $0.088 cash per share plus a contingent value right, is crucial for the micro-cap company, which is trading near its 52-week low. Investors should monitor the final tender results by the new deadline of February 2, 2026, as the successful completion of this offer will fundamentally alter the company's future.